搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 7 天
时间不限
过去 1 小时
过去 24 小时
过去 30 天
按时间排序
按相关度排序
Targeted Oncology
5 小时
Expert Takeaway From WCLC Congress Highlights Innovative ACD Showing Promise in SCLC
Robert L. Ferris, MD, PhD, highlights groundbreaking advancements presented at the recent World Congress on Lung Cancer held ...
Targeted Oncology
9 小时
Revolutionizing CLL Care With Targeted and Cellular Therapies
Cyrus M. Khan, MD, highlights some of the most recent and significant advancements in chronic lymphocytic leukemia treatment.
Targeted Oncology
13 小时
Zakharia Evaluates Available Combination Options for Non–Clear Cell RCC
Yousef Zakharia, MD, discussed some of the available combination therapies for non–clear Cell renal cell carcinoma treatment.
Targeted Oncology
1 天
Pembrolizumab/Chemo Continues to Impress in NSCLC With 5-Year Updates
During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses phase 3 trials of combinations in the non–small cell lung ...
Targeted Oncology
1 天
Evolving Strategies in Hematopoietic Stem Cell Transplant Conditioning
Sergio A. Giralt, MD, discusses what the most commonly used conditioning regimens for patients with myelodysplastic syndrome undergoing transplants are.
Targeted Oncology
1 天
FDA Pushes Back Decision on Sotorasib/Panitumumab in Colorectal Cancer
The FDA was expected to decide on the application of sotorasib and panitumumab for the treatment of metastatic colorectal ...
Targeted Oncology
1 天
Avutometinib/Defactinib Leads to Positive Response, Survival Data in Ovarian Cancer
The completion of a new drug application for the combination of avutometinib and defactinib in KRAS-mutant ovarian cancer is ...
Targeted Oncology
1 天
Examining Safety: Daratumumab With VRd in Transplant-Ineligible Myeloma
Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the safety data from the phase 3 CEPHEUS trial in newly diagnosed multiple myeloma.
Targeted Oncology
1 天
FREEDOM2 Trial Shows Fedratinib’s Efficacy and Safety in Myelofibrosis
The FREEDOM2 study demonstrates that fedratinib is an effective second-line treatment for myelofibrosis after ruxolitinib ...
Targeted Oncology
1 天
Brown-Glaberman Reviews Data for PIK3CA-Altered Metastatic Breast Cancer
During a Case-Based Roundtable® event, Ursa Brown-Glaberman, MD, discussed options for the treatment of patients with ...
Targeted Oncology
2 天
Community Oncologists Show Comfort With Bispecifics in B-Cell Lymphoma
Elizabeth A. Brem, MD, discusses the shift she has seen in the community setting when it comes to using bispecific antibody ...
Targeted Oncology
2 天
Mechanism and Benefits of Rusfertide in Polycythemia Vera
Aniket Bankar, MD, discusses why rusfertide is considered a promising therapeutic approach for patients with polycythemia vera.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈